GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Regencell Bioscience Holdings Ltd (NAS:RGC) » Definitions » Return-on-Tangible-Equity

Regencell Bioscience Holdings (Regencell Bioscience Holdings) Return-on-Tangible-Equity : -39.63% (As of Jun. 2023)


View and export this data going back to 2021. Start your Free Trial

What is Regencell Bioscience Holdings Return-on-Tangible-Equity?

Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Regencell Bioscience Holdings's annualized net income for the quarter that ended in Jun. 2023 was $-5.29 Mil. Regencell Bioscience Holdings's average shareholder tangible equity for the quarter that ended in Jun. 2023 was $13.34 Mil. Therefore, Regencell Bioscience Holdings's annualized Return-on-Tangible-Equity for the quarter that ended in Jun. 2023 was -39.63%.

The historical rank and industry rank for Regencell Bioscience Holdings's Return-on-Tangible-Equity or its related term are showing as below:

RGC' s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: -113.97   Med: -77.17   Max: -40.25
Current: -40.25

During the past 5 years, Regencell Bioscience Holdings's highest Return-on-Tangible-Equity was -40.25%. The lowest was -113.97%. And the median was -77.17%.

RGC's Return-on-Tangible-Equity is ranked worse than
84.67% of 933 companies
in the Drug Manufacturers industry
Industry Median: 6.33 vs RGC: -40.25

Regencell Bioscience Holdings Return-on-Tangible-Equity Historical Data

The historical data trend for Regencell Bioscience Holdings's Return-on-Tangible-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Regencell Bioscience Holdings Return-on-Tangible-Equity Chart

Regencell Bioscience Holdings Annual Data
Trend Jun19 Jun20 Jun21 Jun22 Jun23
Return-on-Tangible-Equity
- - - -113.97 -40.36

Regencell Bioscience Holdings Semi-Annual Data
Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23
Return-on-Tangible-Equity Get a 7-Day Free Trial Premium Member Only - -91.48 -41.93 -40.69 -39.63

Competitive Comparison of Regencell Bioscience Holdings's Return-on-Tangible-Equity

For the Drug Manufacturers - Specialty & Generic subindustry, Regencell Bioscience Holdings's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Regencell Bioscience Holdings's Return-on-Tangible-Equity Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Regencell Bioscience Holdings's Return-on-Tangible-Equity distribution charts can be found below:

* The bar in red indicates where Regencell Bioscience Holdings's Return-on-Tangible-Equity falls into.



Regencell Bioscience Holdings Return-on-Tangible-Equity Calculation

Regencell Bioscience Holdings's annualized Return-on-Tangible-Equity for the fiscal year that ended in Jun. 2023 is calculated as

Return-on-Tangible-Equity=Net Income/( (Total Tangible Equity+Total Tangible Equity)/ count )
(A: Jun. 2023 )  (A: Jun. 2022 )(A: Jun. 2023 )
=Net Income/( (Total Stockholders Equity - Intangible Assets+Total Stockholders Equity - Intangible Assets )/ count )
(A: Jun. 2023 )  (A: Jun. 2022 )(A: Jun. 2023 )
=-5.871/( (17.065+12.03 )/ 2 )
=-5.871/14.5475
=-40.36 %

Regencell Bioscience Holdings's annualized Return-on-Tangible-Equity for the quarter that ended in Jun. 2023 is calculated as

Return-on-Tangible-Equity=Net Income/( (Total Tangible Equity+Total Tangible Equity)/ count )
(Q: Jun. 2023 )  (Q: Dec. 2022 )(Q: Jun. 2023 )
=Net Income/( (Total Stockholders Equity - Intangible Assets+Total Stockholders Equity - Intangible Assets)/ count )
(Q: Jun. 2023 )  (Q: Dec. 2022 )(Q: Jun. 2023 )
=-5.288/( (14.659+12.03)/ 2 )
=-5.288/13.3445
=-39.63 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is two times the semi-annual (Jun. 2023) net income data. Return-on-Tangible-Equity is displayed in the 10-year financial page.


Regencell Bioscience Holdings  (NAS:RGC) Return-on-Tangible-Equity Explanation

Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.


Be Aware

Net Income is used.

Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.


Regencell Bioscience Holdings Return-on-Tangible-Equity Related Terms

Thank you for viewing the detailed overview of Regencell Bioscience Holdings's Return-on-Tangible-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.


Regencell Bioscience Holdings (Regencell Bioscience Holdings) Business Description

Traded in Other Exchanges
N/A
Address
29 Leighton Road, 9/F Chinachem Leighton Plaza, Causeway Bay, Hong Kong, HKG
Regencell Bioscience Holdings Ltd is engaged in the research, development and commercialization of traditional Chinese medicine. The medicines are used for the treatment of neurocognitive disorders and degeneration.

Regencell Bioscience Holdings (Regencell Bioscience Holdings) Headlines

From GuruFocus